Drugs@FDA document
NUCALA Letter · BLA 125526 SUPPL-17
Drugs@FDA document · GLAXOSMITHKLINE LLC · Sep 29, 2020
Key facts
| Drug name | NUCALA |
|---|---|
| Document type | Letter |
| Application | BLA125526 |
| Submission | SUPPL-17 |
| Company | GLAXOSMITHKLINE LLC |
| Document date | Sep 29, 2020 |
| FDA document | accessdata.fda.gov |
At a glance
- Efficacy-New Indication Document categories
- 10–99 Documents for this application
- 1–9 USP chapters cited in this application's documents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA documents
Drugs@FDA posts the letters, labels, reviews and other documents behind each drug application and supplement. Orca1 indexes every document's full text and flags complete response letters.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA application documents · Source date: